Your are the "rlp" not the "rip".
Sure, let us buy as many as we can.
Unlike other cancer drug treatments, NeuVax has a very high safety profile with very low side effects. Of course, NeuVax is highly effective in preventing breast cancer from returning.
What you have said is true.
I do not think we should waste any time with the online Gale predators. First you are giving them a chance to bring their lies to the top. Second, you are making them easier to earn extra bonus.
There is a huge difference between Sexual desire and breast cancer cells. You are comparing apples with oranges !!!
Welcome and well said. Three cheers to you and we will try to keep your message on top.
Keep presenting good facts and good logic whenever you feel like it.
Thanks for sharing this with us, Dan.
This can happen quickly, especially that NeuVax is highly effective in preventing breast cancer from returning and it has a very high safety profile and with very low side effects. The UK and the EU are very progressive in granting approvals.
Abstral sales + Zuplenz sales + $50 million cash on hand + access to $52 million from Lincoln Parks - reduction of cash burn should keep Gale in a good financial standing for at least 2 more years.
Thanks, Dan. I agree with your views here.
As far as I am concern, at this moment Gale is a high risk investment with potentially huge rewards. For those who can accept this risk, buy as much as you can afford and if Gale does not make it in 6 to 24 months, one does not mind losing all of ones investment in Gale.
I am expecting a lot more "red thumbs down" with no response from the online Gale predators as time goes by.
With the recognition of so many positives, Sean is advising us to delay buying until the interim results become known does not make sense to me. He can a least advise prudent buying at this very low price.
NeuVax works by turning on the immune system. NeuVax recruits the main components of the cellular immune system to fight cancer by presentation of a T-cell peptide epitope in the context of the peptide-HLA-T-cell receptor complex. When NeuVax is administered, the E75 peptide, a well established T-cell epitope discovered on HER2, binds to the HLA-A2 and HLA-A3 molecules on the surface of tumor cells and Antigen Presenting Cells (APCs). The peptide sends a signal to the immune system by binding in the HLA-peptide-T-cell receptor complex. Circulating T-cells recognize the peptide bound to HLA though T-cell receptors (TCRs) on their surfaces and the T-cells become “educated” and “activated” to target HER2-expressing tumor cells exhibiting the E75 epitope bound to HLA. Furthermore, activation of these T-cells leads to clonal expansion and proliferation of E75-specific “killer T-cells” that circulate through the body, identify and destroy cancer cells that are processing HER2.
Mechanism of Action: Active Specific Immunotherapy (ASI)
Tumor cells are differentiated from healthy cells by the expression of tumor-associated proteins, also known as “tumor antigens.” HER2/neu is a well established tumor-associated antigen found at various expression levels on the membrane surface of many types of human cancer cells. The human immune system is constantly surveying the body for foreign invaders (foreign proteins) or abnormal self proteins. To aid in this immune surveillance, cellular proteins such as HER2/neu and others are routinely digested or broken down inside the cell into short fragments called peptides and the small peptides are then “displayed” on the cell surface as a means of communicating with the immune system. Differences between the pool of peptides from a tumor cell and a normal cell are revealed on the outside of the cell.